Carisma Therapeutics

OverviewSuggest Edit

Carisma Therapeutics, formerly known as CARMA Therapeutics is a pre-clinical stage biotechnology company that develops novel cellular therapeutics. The Company offers novel cell therapies by re-engineering macrophages expressing CAR, a tumor recognition receptor, enabling the immune system to attack solid tumors. The Company's pipeline is composed of programs, with the potential lead program being for HER-2 expressing tumors.
TypePrivate
Founded2016
HQPhiladelphia, US
Websitecarismatx.com

Latest Updates

Employees (est.) (Jan 2020)28(+4%)

Carisma Therapeutics Office Locations

Carisma Therapeutics has an office in Philadelphia
Philadelphia, US (HQ)
3675 Market St #200
Show all (1)

Carisma Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Carisma Therapeutics total Funding

$62.9 m

Carisma Therapeutics latest funding size

$6 m

Time since last funding

5 months ago

Carisma Therapeutics investors

Carisma Therapeutics's latest funding round in August 2019 was reported to be $6 m. In total, Carisma Therapeutics has raised $62.9 m
Show all financial metrics

Carisma Therapeutics Online and Social Media Presence

Embed Graph

Carisma Therapeutics News and Updates

Carisma Therapeutics Announces Investor Conference Participation

PHILADELPHIA, Nov. 16, 2019 /PRNewswire/ -- Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on engineered macrophages, today announced that it will be participating in three upcoming investor...

Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy

MARLBOROUGH, Mass., Sept. 9, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it has...

Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy

MARLBOROUGH, Mass., Sept. 9, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it has...

Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer

PHILADELPHIA, June 3, 2019 /PRNewswire/ -- Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on engineered macrophages, today announced Robert Petit, Ph.D., as its Chief Scientific Officer. "We...

Carisma Therapeutics Frequently Asked Questions

  • When was Carisma Therapeutics founded?

    Carisma Therapeutics was founded in 2016.

  • How many employees does Carisma Therapeutics have?

    Carisma Therapeutics has 28 employees.

  • Who are Carisma Therapeutics competitors?

    Competitors of Carisma Therapeutics include Athersys, Reata Pharmaceuticals and Otonomy.

  • Where is Carisma Therapeutics headquarters?

    Carisma Therapeutics headquarters is located at 3675 Market St #200, Philadelphia.

  • Where are Carisma Therapeutics offices?

    Carisma Therapeutics has an office in Philadelphia.

  • How many offices does Carisma Therapeutics have?

    Carisma Therapeutics has 1 office.